skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. (Reannouncement with new availability information)

Abstract

The subacute effects of pyridostigmine bromide were investigated on the contractile properties of rat extensor digitorum longus (EDL) and diaphragm muscles. The cholinesterase inhibitor was delivered via subcutaneously implanted osmotic minipumps (Alzet) at 9 microns g h-1 (low dose) or 60 micro g h-1 (high dose). Animals receiving high-dose pyridostigmine pumps exhibited marked alterations in muscle properties within the first day of exposure that persisted for the remaining 13 days. With 0.1 Hz stimulation, EDL twitch tensions of treated animals were elevated relative to control. Repetitive stimulation at frequencies > 1 Hz led a use-dependent depression in the amplitude of successive twitches during the train. Recovery from pyridostigmine was essentially complete by 1 day of withdrawal. Rats implanted with low-dose pyridostigmine pumps showed little or no alteration of in vivo twitch tensions during the entire 14 days of treatment. Diaphragm and EDL muscles excised from pyridostigmine-treated rats and tested in vitro showed no significant alterations in twitch and tetanic tensions and displayed the same sensitivity as muscles of control animals to subsequent pyridostigmine exposures. In the presence of atropine, subacutely administered pyridostigmine protected rats from two LD5O doses of the irreversible cholinesterase inhibitor, soman. In the absence of atropine, themore » LD50 of soman was not altered by subacute pyridostigmine treatment. Extensor digitorum longus; diaphragm; twitch tension; ACh release; subacute; Alzet pumps; tolerance; anticholinesterase; pyridostigmine; soman.« less

Authors:
; ; ; ;
Publication Date:
Research Org.:
Army Medical Research Inst. of Chemical Defense, Aberdeen Proving Ground, MD (United States)
OSTI Identifier:
166865
Report Number(s):
AD-A-250686/3/XAB; USAMRICD-P-89-069
TRN: 53520627
Resource Type:
Technical Report
Resource Relation:
Other Information: PBD: 1992
Country of Publication:
United States
Language:
English
Subject:
45 MILITARY TECHNOLOGY, WEAPONRY, AND NATIONAL DEFENSE; 56 BIOLOGY AND MEDICINE, APPLIED STUDIES; CHEMICAL WARFARE AGENTS; TOXICITY; PREVENTIVE MEDICINE; BROMIDES; THERAPEUTIC USES; CHOLINESTERASE

Citation Formats

Adler, M, Deshpande, S S, Foster, R E, Maxwell, D M, and Albuquerque, E X. Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. (Reannouncement with new availability information). United States: N. p., 1992. Web.
Adler, M, Deshpande, S S, Foster, R E, Maxwell, D M, & Albuquerque, E X. Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. (Reannouncement with new availability information). United States.
Adler, M, Deshpande, S S, Foster, R E, Maxwell, D M, and Albuquerque, E X. 1992. "Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. (Reannouncement with new availability information)". United States.
@article{osti_166865,
title = {Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. (Reannouncement with new availability information)},
author = {Adler, M and Deshpande, S S and Foster, R E and Maxwell, D M and Albuquerque, E X},
abstractNote = {The subacute effects of pyridostigmine bromide were investigated on the contractile properties of rat extensor digitorum longus (EDL) and diaphragm muscles. The cholinesterase inhibitor was delivered via subcutaneously implanted osmotic minipumps (Alzet) at 9 microns g h-1 (low dose) or 60 micro g h-1 (high dose). Animals receiving high-dose pyridostigmine pumps exhibited marked alterations in muscle properties within the first day of exposure that persisted for the remaining 13 days. With 0.1 Hz stimulation, EDL twitch tensions of treated animals were elevated relative to control. Repetitive stimulation at frequencies > 1 Hz led a use-dependent depression in the amplitude of successive twitches during the train. Recovery from pyridostigmine was essentially complete by 1 day of withdrawal. Rats implanted with low-dose pyridostigmine pumps showed little or no alteration of in vivo twitch tensions during the entire 14 days of treatment. Diaphragm and EDL muscles excised from pyridostigmine-treated rats and tested in vitro showed no significant alterations in twitch and tetanic tensions and displayed the same sensitivity as muscles of control animals to subsequent pyridostigmine exposures. In the presence of atropine, subacutely administered pyridostigmine protected rats from two LD5O doses of the irreversible cholinesterase inhibitor, soman. In the absence of atropine, the LD50 of soman was not altered by subacute pyridostigmine treatment. Extensor digitorum longus; diaphragm; twitch tension; ACh release; subacute; Alzet pumps; tolerance; anticholinesterase; pyridostigmine; soman.},
doi = {},
url = {https://www.osti.gov/biblio/166865}, journal = {},
number = ,
volume = ,
place = {United States},
year = {Thu Dec 31 00:00:00 EST 1992},
month = {Thu Dec 31 00:00:00 EST 1992}
}

Technical Report:
Other availability
Please see Document Availability for additional information on obtaining the full-text document. Library patrons may search WorldCat to identify libraries that may hold this item. Keep in mind that many technical reports are not cataloged in WorldCat.

Save / Share: